| Previous Close | 70.48 |
| Open | 71.24 |
| Bid | 70.68 x 200 |
| Ask | 70.69 x 800 |
| Day's Range | 70.29 - 71.37 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 6,285,856 |
| Avg. Volume | 8,066,854 |
| Market Cap | 91.95B |
| Beta | 0.97 |
| PE Ratio (TTM) | 7.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (3.08%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- TheStreet.com•10 minutes ago
Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout
The stock has been on fire.
- Forbes•18 hours ago
Biotech Resurgence Has Bite But No FAANGs
Move over FAANGs, when comparing the performance of the 10 Select Sector SPDR ETFs, healthcare is currently leading in the last 1-week, 6-week and 12-week performance periods. However, it appears the leadership within the healthcare sector is changing. Here's the short list with analysis.
- Investor's Business Daily•19 hours ago
Why The Biotech Rally Could Still Tack On Another 15% Upside
Celgene, Regeneron and Vertex could lead the biotech sector to 15% more upside following the second quarter, an analyst said Thursday.
